Author Correction: Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-1723
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Author Correction: Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice ; volume:10 ; number:1 ; day:16 ; month:1 ; year:2019 ; pages:1 ; date:12.2019
Nature Communications ; 10, Heft 1 (16.1.2019), 1, 12.2019
- Urheber
-
Rossin, Raffaella
Versteegen, Ron M.
Wu, Jeremy
Khasanov, Alisher
Wessels, Hans J.
Steenbergen, Erik J.
Hoeve, Wolter ten
Janssen, Henk M.
Onzen, Arthur H. A. M. van
Hudson, Peter J.
Robillard, Marc S.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-019-08376-x
- URN
-
urn:nbn:de:101:1-2019020111441081533049
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rossin, Raffaella
- Versteegen, Ron M.
- Wu, Jeremy
- Khasanov, Alisher
- Wessels, Hans J.
- Steenbergen, Erik J.
- Hoeve, Wolter ten
- Janssen, Henk M.
- Onzen, Arthur H. A. M. van
- Hudson, Peter J.
- Robillard, Marc S.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein